Latest News

The toxicity of our beta-amyloid peptide oligomers is confirmed in vivo in elderly mice After several months’ development, several replicated studies show that oligomers of A-beta peptides (whose neurotoxicity in vitro is well documented), induce cognitive deficits in object recognition test and Morris watermaze in the weeks following intracerebroventricular injection in 18-month-old mice. We have shown that the administration of A-beta 1-42 oligomers leads to significant memory impairment in the object recognition test: while animals in the vehicle group show a significant

All of us here at ETAP-Lab and STROK@LLIANCE hope all of you are in good health, and wish you every success in all your endeavours, in 2021 and beyond. As we approach the end of this year unlike any other, we wanted to let you know how ETAP-Lab has managed - and share our plans for 2021 with you. During the health crisis Despite two periods of lockdown ETAP-Lab’s activity has not diminished - quite the opposite, in fact! Having ground to an

In partnership with Lallemand Health Solutions, Aspen Farmacêutica is bringing the first psychobiotic formulation for the gut-brain axis to the Brazilian market. The two finished products are Probid and Probians and contain two strains of probiotics for which the following claims are now approved: Lactobacillus helveticus Rosell-52 and Bifidobacterium longum Rosell-175 may contribute to the reduction of feelings of anxiety in healthy individuals. Lactobacillus helveticus Rosell-52 and Bifidobacterium longum Rosell-175 contribute to the reduction of gastrointestinal complications (such as abdominal pain and nausea/vomiting) brought on by light

Preclinical research carried out in a rat skin healing model that has shown the efficacy of a sucrose octasulfate dressing (UrgoStart) will be presented at the EWMA Digital Congress - 18 and 19 November 2020. We were able to show that the accelerated healing achieved by use of the innovative UrgoStart dressings was linked to faster and denser reconstruction of the local vascular network, in comparison with control conditions in rats. These results, invaluable for URGO laboratories, have made it possible

The toxicity of the tau oligomers produced by ETAP-Lab can be reversed by using BDNF on primary rat neuron cultures. BNDF applied at the same time as tau oligomers significantly and reproducibly reduced cell mortality.   Incubation of cortical neurons with Tau monomers, TauO and TauO+BDNF. TauO decreased quite significantly cell viability (*; p<0.01), while monomers showed no neurotoxic effect. Incubation with BDNF significantly reversed TauO-induced neurotoxicity (#; p<0.01). Data are expressed as percent of vehicle (set at 100%) and represent the mean ± SD. (N=3, n=12).   This tauopathy model is now

ETAP-Lab a is expanding and recruiting a new employee for STROK@LLIANCE: there is a new Laboratory technician – Research assistant position available at STROK@LLIANCE(Caen, FRANCE). Please find here the If you fit to this profile, please contact us at recruitment@etap-lab.com Un nouveau poste de technicien de laboratoire – assistant de recherche est ouvert chez STROK@ALLIANCE (Caen, FRANCE). La description du poste est disponible

The new tau oligomers produced by ETAP-Lab show reproducible and dose-dependent toxicity on rodent primary neuron cultures. Promising and repeatedly replicated data show that tau oligomers exhibit dose-dependent toxicity that is not observed with equivalent monomer concentrations. At high concentrations, the oligomers completely destabilise the neurons, leading to a rapid mortality rate of 100%.     Now that the main technical obstacles have been overcome, a validated model for pharmacological screening should be ready soon. The next step is to evaluate some reference compounds.

ETAP-Lab will be attending BIO-Japan 2020 as part of the Business France virtual French pavilion. We are delighted to have this unprecedented opportunity to reach out to the Japanese market. We will be at BIO Japan 2020 throughout, from 14 to 16 October. Our experts Dr. Jean-François Bisson (VP) and Dr. Nicolas Violle (CEO) will be there to introduce you to the laboratory's activities in preclinical Neurology, Dermatology and Nutrition-Health. Please feel free to contact us to schedule a video conference. We’re hoping

Have your preclinical R&D projects fallen behind schedule during lockdown? Every industrial activity has been knocked sideways by the COVID-19 emergency - and healthcare R&D is no exception. Because we’ve been busy preparing the ground for the recovery ever since the start of lockdown, we are ready to support you as best we can in the intense catch-up period that is to come. Many of the studies we helped plan during lockdown are already under way. We are glad to see our customers